Professional Documents
Culture Documents
الصيادلة المهنيين
الصيادلة المهنيين
Blood vessels
Transdermal absorption
Skin
G.I.T
,Stomach) Liver
(Intestine
1.4
1.2
Composition of the
Prepared Transdermal
Formulations
Water soluble bases:bases
Polyethylene glycol base: (U.S .P .XXII).
PEG 4000 6 gm
PEG 400 4 gm
Emulsion bases (O/W
emulsion base)
10 g
(Emulgel (O/W Emulgel
Ethanol 18ml
Water 7ml
HPMC 0.4gm
PEG400 0.1gm
DRUG 0.056gm
Part :1
Release studies
through the natural
rabbit skin
((in vitro study
Using Diffusion tester and natural rabbit
. skin
In case of ointment, emulsion and emulgel,
1gm of the tested formulation contains 5 mg
of Glibenclamide was weighed in a
diffusion cell (basket(. While the film was
(.cut into pieces (4.7 cm2 contains 5 mg
the dermal side was directed toward the
receptor compartment and the stratum
. corneum facing the donor compartment
Dissolution
Diffusion
Results
Amount Released of Glibenclamide from different
formulations via the natural rabbit skin
Base Amount of drug released in mg after the following time
interval (hrs)
1 2 3 4 5
PEG
3
Kinetic data of Glibenclamide released from
different formulations using natural rabbit skin
Formula (Correlation coefficient (r The observed Slope
order
24 alive
Rabbits
were used
for testing
the release
of
Glibenclami
de in
fasting and
random
A- The Prepared B- Shaved rabbit
Film
C- Blood D- Glucometer
* Blank and oral, the reading was the average of three rabbits in each experiment.
** Transdermal , the reading was the average of six rabbits in each experiment.
In-Vivo Studies Results
Comparison between oral and transdermal
Glibenclamide in blood glucose of fasting rabbits
Time (hrs(
Average Blood glucose mg/dl ( Fasting rabbits(
1 111 63 95.2
2 110 42 67.8
3 108 59 79.7
4 105 72 95.3
F ig .2 :
1 4 0 .0
1 3 0 .0 1 2 8
1 2 3 .3
1 2 0 .0
116
1 1 0 .0
Comparison between average of oral and
transdermal Glibenclamide in blood glucose
of Random rabbits
Time (hrs( Average Blood glucose mg/dl ( Random rabbits(
0 92 100 99.4
1 97 54 81.0
2 109 52 76.2
3 96 63 86.7
4 103 70 90.8
5 98 85 96.0
6 97 90 104.4
F ig : ) T h e
1 2 0 .0
1 1 0 .0
1 0 0 .0 19 09 0.4
Conclusion of in-vivo study